PRMT7 in cancer: Structure, effects, and therapeutic potentials

Area of Science:

• Biochemistry and Molecular Biology
• Cancer Research
• Drug Discovery

Background:

• Protein arginine methyltransferase 7 (PRMT7) is a unique type III methyltransferase catalyzing arginine mono-methylation.
• Aberrant PRMT7 expression and mutations are linked to tumorigenesis, cancer progression, and drug resistance.
• PRMT7 is recognized as a promising therapeutic target for various cancers.

Purpose of the Study:

• To provide a comprehensive overview of PRMT7's molecular structure and function in cancer.
• To analyze PRMT7 inhibitors, including binding modes and structure-activity relationships.
• To identify challenges and propose future directions for PRMT7-targeted drug development.

Main Methods:

• Literature review of PRMT7's role in different cancer types.
• Analysis of existing PRMT7 inhibitor data, focusing on structure-activity relationships.
• Discussion of challenges and future strategies in PRMT7 drug discovery.

Main Results:

• PRMT7's critical roles in physiological and pathological processes, particularly in cancer, are detailed.
• Insights into the molecular mechanisms of PRMT7 in various cancers are presented.
• Structure-activity relationships and binding modes of PRMT7 inhibitors are analyzed.

Conclusions:

• PRMT7 is a significant target for cancer therapy due to its involvement in tumorigenesis and drug resistance.
• Understanding PRMT7's structure and inhibition is key to developing effective cancer drugs.
• Overcoming current challenges will facilitate the advancement of PRMT7-targeted cancer therapeutics.